Reply to @TheChosen
As I understand it, IMU is not funding the PD1-Vaxx PH2 “Neo-POLEM” trial.
I think a few people have misinterpreted deprioritised as shelving, which hasn’t happened (yet). Instead, they’ve wound back their financial commitment to both PD1-Vaxx and HER-Vaxx. PD1-Vaxx because someone else is funding the Ph2 and HER-Vaxx because Ph2(combo) is almost complete and almost certainly the only way to progress it further is to licence(or sell) it out to someone else, due to the cost/risk ratio and higher likelihood of commercial success offered by the CF33 based platforms and Azer-cel.
Reply to @TheChosenAs I understand it, IMU is not funding the...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $490.4M | |||
| Open | High | Low | Value | Volume |
| 6.8¢ | 6.9¢ | 6.6¢ | $647.9K | 9.625M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 309078 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 759722 | 11 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.7¢ |
Change
0.000 ( 0.15 %) |
||||
| Open | High | Low | Volume | ||
| 6.8¢ | 6.9¢ | 6.6¢ | 3602017 | ||
| Last updated 15.57pm 31/05/2024 ? | |||||
| IMU (ASX) Chart |